Cargando…
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
Enzalutamide, a second-generation small-molecule inhibitor of the androgen receptor (AR), has been approved for patients who failed with androgen deprivation therapy and have developed castration-resistant prostate cancer. More than 80% of these patients develop bone metastases. The binding of enzal...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992404/ https://www.ncbi.nlm.nih.gov/pubmed/29911070 http://dx.doi.org/10.3389/fonc.2018.00180 |